lenalidomide has been researched along with Bone Loss, Osteoclastic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Christopoulou, G; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gerofotis, A; Kastritis, E; Katodritou, E; Konstantinidou, P; Kourakli, A; Ntanasis-Stathopoulos, I; Symeonidis, A; Terpos, E; Zagouri, F | 1 |
| Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gkotzamanidou, M; Kastritis, E; Katodritou, E; Koulieris, E; Kyrtsonis, MC; Michalis, E; Papanikolaou, X; Papatheodorou, A; Pouli, A; Terpos, E; Zervas, K | 1 |
| Anderson, KC; Breitkreutz, I; Chauhan, D; Hideshima, T; Mitsiades, C; Munshi, NC; Okawa, Y; Raab, MS; Raje, N; Richardson, PG; Vallet, S | 1 |
2 trial(s) available for lenalidomide and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Alkaline Phosphatase; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Bone Resorption; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Female; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Peptide Fragments; Procollagen; Ribonuclease, Pancreatic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Topics: Antineoplastic Agents; B-Cell Activating Factor; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Cathepsin K; Cathepsins; Cells, Cultured; Chemokine CCL3; Humans; Integrin alphaVbeta3; Lenalidomide; Multiple Myeloma; Osteoclasts; Osteoprotegerin; Proto-Oncogene Proteins; Pyrazines; RANK Ligand; Thalidomide; Trans-Activators; Transcription Factor AP-1; Tumor Necrosis Factor Ligand Superfamily Member 13 | 2008 |
1 other study(ies) available for lenalidomide and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Bone Resorption; Dexamethasone; Female; Greece; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Osteogenesis; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |